Eli Lilly’s obesity drug Zepbound improved liver scarring in mid-stage MASH study

Eli Lilly’s blockbuster diabetes and obesity drug improved liver scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year.

The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The percentage of patients who experienced a greater than one-stage improvement in scarring, or fibrosis, without worsening of their disease was ​​54.9%, 51.3%, and 51.0% from the lowest to highest doses.

When compared with the 29.7% of patients on placebo who achieved this outcome, the results were statistically significant, according to an abstract of data that will be presented at the annual meeting of the European Association for the Study of the Liver.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In